

RealRate

PHARMACEUTICAL 2022

## Hepion Pharmaceuticals Inc. Rank 113 of 466









PHARMACEUTICAL 2022



## RealRate

Hepion Pharmaceuticals Inc. Rank 113 of 466

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Hepion Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 145% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	97,452
Cost of Goods Sold	0
Intangible Assets	1,871
Liabilities, Current	8,206
Liabilities, Non-Current	50
Other Assets	4,077
Other Compr. Net Income	0
Other Expenses	8.9
Other Liabilities	2,301
Other Net Income	-2,310
Other Revenues	0
Property and Equipment	153
Research and Development	20,395
Selling, General and Administrative Expense	10,008

Output Variable	Value in 1000 USD
Assets	103,552
Liabilities	10,557
Expenses	30,412
Revenues	0
Stockholders Equity	92,995
Net Income	-32,722
Comprehensive Net Income	-32,722
Economic Capital Ratio	223%

